Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791966 | 0.90 | F7 (0.40) | ALDH1A1KMT2AMEN1CFTRRAB9A | |
| SCHEMBL23461160 | 0.79 | CYP1A2 (0.48) | ALDH1A1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL6790731 | 0.76 | F7 (0.46) | ALDH1A1KMT2AMEN1CFTRRAB9A | |
| SCHEMBL5846166 | 0.71 | F2 (0.50) | ALDH1A1KMT2AMEN1CFTRRAB9A | |
| SCHEMBL23460627 | 0.70 | CYP1A2 (0.46) | ALDH1A1KMT2AMEN1RAB9AMAPT | |
| SCHEMBL23460798 | 0.69 | F2 (0.47) | ALDH1A1KMT2AMEN1RAB9AGAA | |
| SCHEMBL6162376 | 0.69 | ALOX5 (0.59) | ALDH1A1KMT2AMEN1MAPTGAA | |
| SCHEMBL12856432 | 0.67 | ALOX5 (0.61) | ALDH1A1KMT2ARAB9AMAPTALOX5 | |
| SCHEMBL5335470 | 0.67 | KMT2A (0.60) | ALDH1A1KMT2ARAB9AMAPTALOX5 | |
| SCHEMBL6779464 | 0.67 | RAB9A (0.50) | ALDH1A1KMT2ARAB9AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | ALDH1A1 1468/4885KMT2A 4477/4885MEN1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.